top of page
HCL Review
nexus institue transparent.png
Catalyst Center Transparent.png
Adaptive Lab Transparent.png
Foundations of Leadership
DEIB
Purpose-Driven Workplace
Creating a Dynamic Organizational Culture
Strategic People Management Capstone

The Benefits Breaking Point: Rising Health Costs, the GLP-1 Dilemma, and How Leaders Can Keep Coverage Affordable, Fair, and Worth Having

5 hours ago
28 min read

Download the article here:


Listen to a review of this article:


Abstract: Employer-sponsored health coverage, which protects almost 157 million Americans under 65, is under acute strain. KFF's 2026 Employer Health Benefits Survey finds that workers now contribute an average of $7,471 a year toward family coverage, up 9% in a single year, while total family premiums reached $28,303. Employers project 2027 cost growth of 8% to 9% after plan changes, the steepest in two decades, driven by hospital prices, specialty drugs, and rising use of GLP-1 medications for weight management. This article examines how organizations are responding, from cost-shifting and coverage withdrawals to reference-based pricing, value-based design, and structured obesity-care pathways. Drawing on health economics, organizational justice, and documented employer decisions across public, health care, retail, insurance, and higher education settings, it argues that blunt cost-shifting erodes both health and trust. It offers evidence-based responses that treat benefits as a governed investment rather than an annual budget negotiation.

 

Every autumn, open enrollment arrives with a familiar ritual. Employees receive a packet, skim the premium table, notice that their paycheck deduction has crept up again, and choose whatever plan they chose last year. This year, that ritual carries more weight than usual. On October 22, 2026, KFF released its 28th annual Employer Health Benefits Survey, and the headline number was hard to miss: the average worker with family coverage now pays $7,471 a year toward the premium, a 9% jump from 2025 (KFF, 2026a). Total family premiums, including the employer's share, reached $28,303. Reporting on the release, STAT framed the moment as a possible breaking point, with employers running out of conventional ways to absorb rising costs (Bannow, 2026).

 

The forward-looking signals are no softer. Marsh's preliminary 2026 national survey of more than 1,800 employers projects that total health benefit cost per employee will rise 8.2% in 2027 even after planned cost-reduction measures, the highest increase since 2003, and about 11% if employers changed nothing (Marsh, 2026). Business Group on Health's survey of large employers projects a median trend of 9.2% before plan changes (Business Group on Health, 2026). Both identify a now-familiar set of drivers: hospital prices, specialty pharmacy, high-cost cancer and rare-disease therapies, and the rapid growth of glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Wegovy) and tirzepatide (Zepbound) prescribed for weight management.

 

This is not only a finance problem. For most working-age Americans, the employer is the gateway to health care. Almost 157 million people under 65 depend on employer-sponsored coverage (KFF, 2026a). When the cost of that coverage rises faster than wages, the burden lands on household budgets, on access to care, and on the relationship between workers and the organizations they work for. Leaders who treat the annual renewal as a purely actuarial exercise miss the point that benefits are one of the most tangible signals an organization sends about whether it values its people.

 

The practical stakes are high and immediate. Many organizations are finalizing 2027 plan designs now. Some will raise employee contributions; some will drop coverage for GLP-1 drugs used for weight loss; some will narrow networks or add prior authorization. Each of those choices has consequences for health, retention, and trust that rarely appear in the renewal spreadsheet. A smaller group of employers is taking a different path: tightening purchasing discipline, redesigning plans around value, structuring access to expensive therapies rather than banning them, and communicating openly about trade-offs. The evidence suggests that the second path, while harder, protects both the budget and the employment relationship more effectively over time.

 

This article synthesizes what is known about the drivers and consequences of the current cost surge and offers leaders an evidence-based playbook. It draws on the latest employer surveys, peer-reviewed research in health economics and organizational behavior, and documented decisions by employers ranging from state governments and universities to hospital systems, insurers, and retailers.

 

 

The Health Benefits Cost Landscape

 

Defining Key Terms

A few definitions help frame the discussion. Employer-sponsored insurance refers to health coverage that an employer offers to employees and, often, their dependents, with the employer paying a share of the premium. The premium is the total annual price of coverage; the worker contribution is the portion deducted from pay. Cost-sharing refers to what enrollees pay when they use care, including deductibles (the amount paid before the plan begins to pay), copayments (fixed charges), and coinsurance (a percentage of the bill). Cost-shifting is the strategy of moving a larger share of total costs from the employer to employees through higher contributions or cost-sharing.

 

Most large employers are self-funded, meaning they pay claims directly and hire an insurer or third-party administrator to run the plan, rather than buying a fully insured product. KFF (2026b) reports that 71% of covered workers are in self-funded plans, rising to 85% at large firms. Self-funding matters because it makes the employer the direct purchaser of care and drugs, with fiduciary responsibilities under the Employee Retirement Income Security Act (ERISA) to manage plan assets prudently and in participants' interests. Self-funded employers typically rely on a pharmacy benefit manager (PBM) to negotiate drug prices, build formularies (lists of covered drugs), and process prescriptions.

 

GLP-1 receptor agonists are medications that mimic a gut hormone involved in appetite and blood-sugar regulation. Originally developed for type 2 diabetes, several are now approved for chronic weight management. In pivotal trials, once-weekly semaglutide produced mean weight loss of about 15% over 68 weeks compared with about 2% for placebo (Wilding et al., 2021), and tirzepatide produced mean reductions of up to roughly 21% at the highest dose over 72 weeks (Jastreboff et al., 2022). The SELECT trial found that semaglutide reduced the risk of major adverse cardiovascular events by 20% among adults with overweight or obesity and established cardiovascular disease but without diabetes (Lincoff et al., 2023). These are meaningful clinical benefits, which is precisely why coverage decisions are so fraught.

 

Finally, value-based insurance design (VBID) is an approach that sets cost-sharing according to the clinical value of a service rather than its price, lowering barriers to high-value care while discouraging low-value care (Chernew et al., 2007). Reference-based pricing sets what a plan will pay providers by reference to a benchmark, commonly a multiple of Medicare rates, rather than accepting negotiated discounts off billed charges.

 

Prevalence, Drivers, and Distribution

The scale of the cost increase is clearest in the KFF data. Average annual premiums in 2026 are $9,804 for single coverage and $28,303 for family coverage, each up 5% from 2025 (KFF, 2026b). Over the past five years, family premiums have risen 28%, slightly ahead of wages (26.9%) and inflation (24.4%). Worker contributions to family coverage rose 26% over the same period, but the most recent year saw a particularly sharp jump of 9% (KFF, 2026a).

 

The burden is not evenly distributed. Workers at small firms (10 to 199 employees) contribute an average of $9,687 a year toward family coverage, compared with $6,840 at large firms. Nearly a third of covered workers at small firms (32%) must pay more than half the family premium, compared with 6% at large firms, and 31% of small-firm workers with family coverage contribute $12,000 or more a year (KFF, 2026b). Deductibles show the same pattern: among workers facing a single-coverage deductible, the average is $1,955 overall but $2,624 at small firms. Regional variation is also substantial, with average family premiums of $31,378 in the Northeast compared with $26,702 in the South.

 

Several drivers explain the acceleration. The first is provider prices. In the Business Group on Health (2026) survey, 62% of large employers said hospital price increases drive their costs to a great or very great extent, and the organization reports that employer costs have risen by a projected 76% cumulatively from 2018 through 2027. Hospital consolidation has given many health systems substantial pricing power in commercial markets, and employers, unlike Medicare, typically pay negotiated rates that are a multiple of public program rates.

 

The second driver is pharmacy, which now represents about a quarter of total health spending for large employers, with 95% expressing concern about drug costs (Business Group on Health, 2026). Specialty drugs for cancer, autoimmune conditions, and rare diseases account for a growing share. Within pharmacy, GLP-1 drugs have become the single most visible pressure point. Marsh (2026) estimates that rising GLP-1 use for weight management accounts for about one percentage point of the overall 2027 cost growth. Jefferson Health's chief executive told NBC News that prescription drugs accounted for 40% of the system's insurance spending in 2025, up from 14% a decade earlier, and attributed about a third of its insurance division's roughly $180 million loss to GLP-1 spending (Becker's Payer Issues, 2026).

 

The third driver is high-cost claims. New cell and gene therapies, cancer treatments, and treatments for rare diseases can each cost hundreds of thousands of dollars. Cancer is a top-three cost condition for 92% of large employers (Business Group on Health, 2026). For self-funded employers, a handful of catastrophic claims can swing an entire year's results.

 

Employers are responding, but in ways that frequently move costs rather than reduce them. Among large firms, 44% increased the share of the premium that workers pay in response to projected cost increases this year, rising to 66% among employers with 5,000 or more workers; 21% raised deductibles or cost-sharing for most services; and smaller shares changed insurers, added utilization management, or moved to narrower networks (KFF, 2026b).

 

GLP-1 coverage decisions illustrate the tension most sharply. Only 18% of firms with 200 or more workers cover GLP-1s specifically for weight loss, rising to 33% among firms with 5,000 or more workers. Among covering firms, 29% describe the effect on prescription drug spending as significant and 27% as moderate. Among firms that do not currently cover these drugs for weight loss, 12% report stopping coverage in the last twelve months, and 79% say they are not likely to begin coverage in the coming year (KFF, 2026b). Business Group on Health (2026) reports that 14% of large employers have dropped or will drop GLP-1 weight-loss coverage in 2027. Meanwhile, GoodRx estimates cited by NPR suggest that about 12 million people lost coverage for each of Zepbound and Wegovy between 2025 and 2026 as formularies and employer plans tightened (NPR, 2026).

 

Organizational and Individual Consequences

 

Organizational Performance Impacts

For employers, the most immediate consequence is budgetary. Health benefits are typically the largest non-wage component of compensation, and when they grow faster than revenue, they crowd out other investments. Economic research has long shown that the burden of rising premiums does not stay with employers. Baicker and Chandra (2006) found that increases in health insurance premiums are associated with slower wage growth and shifts in employment, including toward part-time work that does not carry benefits. In other words, whatever the employer's intentions, workers tend to pay for rising health costs, either directly through contributions or indirectly through forgone raises. That reality makes the efficiency of health spending a direct workforce issue, not only a finance one.

 

Benefits also shape talent flows. Health insurance has historically been one of the strongest forces holding workers in place. Madrian (1994) documented "job lock," in which workers who would lose coverage by changing jobs were significantly less likely to move. Job lock can look like retention, but it is a fragile and sometimes unhealthy form of attachment: employees who stay primarily to keep coverage may be disengaged, and when coverage erodes, the anchor weakens. Conversely, when benefits feel generous and reliable, they function as a powerful signal of organizational support, which meta-analytic research links to higher commitment, performance, and lower turnover intentions (Kurtessis et al., 2017; Rhoades & Eisenberger, 2002).

 

There is also a governance consequence. Self-funded employers are fiduciaries for their health plans. In recent years, participants have filed lawsuits alleging that large employers breached those duties by overpaying for prescription drugs. In Lewandowski v. Johnson & Johnson, former employees alleged that the company's plan paid prices for some generic drugs far above what the same drugs cost at retail pharmacies; the federal court in New Jersey dismissed the case for a second time in December 2025 on standing grounds (PlanAdviser, 2025). A similar case against Wells Fargo was dismissed in Minnesota in March 2025 because plaintiffs had not shown a concrete individual injury (Buchanan Ingersoll & Rooney, 2025). Although these suits have so far failed on procedural grounds, they have put plan sponsors on notice that drug purchasing is a fiduciary matter, and the Consolidated Appropriations Act (2020) added transparency obligations, including a prohibition on so-called gag clauses that block plan sponsors from seeing their own cost and quality data. The KFF survey finds that only 49% of large firms say they receive sufficient information about rebates and other payments flowing from manufacturers to their insurer, administrator, or PBM (KFF, 2026a).

 

Small and mid-sized employers face a sharper version of the same squeeze. They have less bargaining power, fewer administrative resources, and less ability to spread the risk of a single catastrophic claim. KFF (2026b) finds that 67% of firms with ten or more workers offer health benefits, and that 92% of workers are employed by a firm that offers coverage, but only 55% of all workers are actually covered by their own employer's plan once eligibility rules and take-up decisions are considered. Some employers that do not offer traditional group coverage are experimenting with alternatives: KFF (2026a) reports that 11% of non-offering employers use individual coverage health reimbursement arrangements, which give workers tax-advantaged funds to purchase individual-market coverage. Such arrangements can offer predictability to employers, but they shift the work of choosing and navigating coverage onto employees, which makes the quality of decision support even more important.

 

Finally, poorly designed cost containment can backfire financially. Research on deductibles shows that when employees face higher out-of-pocket costs, they cut back on care broadly, including care that is likely to be valuable, and they do not become effective price shoppers. Brot-Goldberg et al. (2017) studied a large self-insured firm that moved all employees into a high-deductible plan and found that spending fell almost entirely through reduced quantities of care, with no evidence that employees shifted toward lower-priced providers. Reduced use of preventive and chronic-disease care can raise costs later through avoidable complications, absences, and disability.

 

 

Individual Wellbeing and Stakeholder Impacts

For employees and their families, rising contributions and deductibles translate directly into financial strain. A worker paying $7,471 a year toward a family premium, and facing a deductible on top of it, is committing a significant share of take-home pay to coverage before receiving any care. KFF's earlier national survey on health care debt estimated that about four in ten U.S. adults carried debt from medical or dental bills (Lopes et al., 2022). Financial strain spills into work through distraction, stress, and absenteeism.

 

Cost-sharing also changes how people use care. The finding that high deductibles reduce use of valuable as well as wasteful care (Brot-Goldberg et al., 2017) is complemented by evidence that removing cost barriers for high-value medications improves adherence and outcomes. In a randomized trial among patients discharged after a heart attack, eliminating copayments for preventive cardiac medications improved adherence and reduced rates of first major vascular events without increasing total health spending (Choudhry et al., 2011). The implication is that cost-sharing is a blunt instrument: it can reduce spending, but the reductions often fall on exactly the care employers should want employees to receive.

 

GLP-1 coverage withdrawals create a distinctive set of wellbeing effects. Obesity is a chronic disease with substantial consequences for cardiovascular, metabolic, and musculoskeletal health, and the SELECT trial demonstrates that treatment can reduce serious cardiovascular events (Lincoff et al., 2023). Yet discontinuation is common and has consequences. When participants in the STEP 1 trial stopped semaglutide, they regained about two-thirds of their prior weight loss within a year (Wilding et al., 2022). Real-world persistence is low: an analysis of commercially insured adults without diabetes found that only about one in twelve remained on therapy three years after starting (Urick et al., 2025). Employees who lose coverage often face a difficult choice between paying cash, switching to compounded versions that do not go through FDA approval, or stopping treatment. NPR reported the experience of a school district employee whose plan dropped Wegovy while her monthly premium rose 20%, attributed by her insurance trust to GLP-1 costs; she eventually switched to a compounded product (NPR, 2026). At UVA Health, about 60% of one obesity specialist's roughly 1,000 patients on these drugs were paying out of pocket.

 

Equity concerns run through all of these effects. Flat-dollar premium contributions take a much larger bite from the pay of a frontline worker than from that of an executive, and the same deductible represents a very different financial risk at different income levels. Because lower-wage workers are also more likely to be employed by small firms, where contributions and deductibles are highest (KFF, 2026b), the burden of rising costs is regressive by default unless employers deliberately design against it. The consequences can show up in patterns of care that employers rarely see directly: delayed prescriptions, skipped follow-up visits, and chronic conditions that are managed later and more expensively than they should be.

 

The stakeholder effects extend beyond employees. Dependents, including children and spouses, share in coverage changes. Health systems and clinicians bear the administrative burden of prior authorization and formulary churn. Communities feel the effect when coverage retreats in large public employers, which are often among the biggest employers in their regions. And for the organization's own leaders, coverage decisions carry reputational weight: decisions about which conditions merit coverage are read by employees as statements about whose health matters.

 

Perceptions of fairness amplify all of these effects. Organizational justice research shows that people react not only to outcomes but to how decisions are made and explained (Colquitt et al., 2001). A premium increase or coverage change that is explained transparently, applied consistently, and accompanied by genuine alternatives is experienced very differently from one that appears without warning in an enrollment portal. Psychological contract research adds that when employees perceive that the organization has broken implicit promises, the result is reduced trust, satisfaction, and commitment, and increased intention to leave (Zhao et al., 2007). Health benefits are among the most salient elements of that implicit contract.

 

Evidence-Based Organizational Responses


The evidence points toward five responses that, together, offer an alternative to the cycle of annual cost-shifting. Table 1 summarizes them before each is examined in turn.


Table 1. Evidence-based responses to rising health benefit costs.

Response

Evidence Base

Key Practices

Illustrative Examples

Govern purchasing like a fiduciary

Fiduciary litigation; transparency law; price variation research

PBM audits and transparent contracts; data rights; reference-based pricing; vendor performance guarantees

Montana State Health Plan; Johnson & Johnson and Wells Fargo litigation

Design for value, not just cost

Deductible studies; value-based insurance design trials

Protect high-value care from cost-sharing; target low-value care; tie contributions to ability to pay

Aetna post-heart-attack trial; large-firm high-deductible study

Make structured, evidence-based GLP-1 decisions

Clinical trials; persistence data; employer cost experience

Clinical criteria; lifestyle and clinical support pathways; transition plans; scheduled re-evaluation

Jefferson Health; State of Connecticut; North Carolina; University of Missouri; Cigna; HCA Healthcare

Steer to high-quality care

Centers of excellence results; navigation programs

Centers of excellence; on-site and near-site clinics; second opinions; navigation

Walmart centers of excellence

Communicate with candor and build literacy

Health insurance literacy research; organizational justice

Explain trade-offs early; decision support; employee input; consistent rationale

University of Missouri

 

Govern Purchasing Like a Fiduciary

The first response begins with an uncomfortable recognition: many employers do not know what they are paying for. Self-funded plan sponsors often rely on intermediaries whose compensation depends on the very prices they negotiate, and only about half of large firms say they receive sufficient information about manufacturer rebates and other payments (KFF, 2026a). Purchasing discipline means treating the health plan as a large procurement function subject to the same rigor as any other major spend. Large employers are moving in this direction. Business Group on Health (2026) reports that 95% of surveyed employers have issued requests for proposals, 83% have expanded performance guarantees with vendors, 71% have tied a larger share of vendor fees to outcomes, and 32% plan to offer a transparent PBM arrangement in 2027, with 47% more considering one for 2028 or 2029.

 

The legal environment reinforces this shift. Transparency provisions enacted in the Consolidated Appropriations Act, 2021 (2020) prohibit agreements that prevent plan sponsors from accessing their own cost and quality data. Litigation against Johnson & Johnson and Wells Fargo, although dismissed on standing grounds, has drawn attention to how plans pay for generic drugs and how PBM arrangements can inflate costs (Buchanan Ingersoll & Rooney, 2025; PlanAdviser, 2025). Prudent process, documented decisions, and benchmarking are both good management and good legal hygiene.

 

Effective approaches:

 

  • Claim your data: Negotiate contracts that guarantee full access to claims, pricing, and rebate data, and audit them periodically.

  • Benchmark prices: Compare what the plan pays for hospital services and drugs against Medicare rates and transparent market benchmarks.

  • Align incentives: Prefer pass-through or transparent PBM models and tie vendor compensation to measurable outcomes.

  • Document prudence: Establish a benefits committee with a charter, minutes, and a regular review cycle, as ERISA fiduciaries would for a retirement plan.

  • Consider alternative pricing: Evaluate reference-based pricing or direct contracts where provider markets permit.

 

The Montana State Employee Health Plan offers one of the best-documented examples of what purchasing discipline can achieve. In 2014, the plan covered about 30,000 lives and faced a projected $28.9 million loss that put it on course for insolvency by 2017. Under the leadership of Marilyn Bartlett, a certified public accountant who became the plan's administrator, the state moved to reference-based pricing, paying hospitals an average of about 2.2 to 2.5 times Medicare rates rather than negotiated discounts off charges. The plan reported up to $47.8 million in hospital savings over three years, a 23% reduction in drug costs after replacing its PBM, and reserves that reached $112 million by 2017 instead of the projected deficit (Journal of Accountancy, 2023). Montana's experience also shows the fragility of such reforms: a later change in administrator raised concerns that transparency gains could erode, a reminder that purchasing discipline must be institutionalized rather than dependent on a single leader.

 

The pitfall here is treating procurement as a one-time event. A competitive bid can lower prices for a year, but without ongoing data access, audits, and accountability, savings drift back. Purchasing discipline is a capability, not a transaction.

 

Design for Value, Not Just Cost

The second response addresses plan design. The research on cost-sharing is consistent: higher deductibles and copayments reduce use of care, but they do so indiscriminately. Brot-Goldberg et al. (2017) found that when a large employer moved all workers into a high-deductible plan, spending fell through reduced quantities of care, including care likely to be valuable, with no evidence of price shopping. Choice is not a reliable corrective. Loewenstein et al. (2013) found that a large share of insured Americans could not correctly answer basic questions about deductibles, copayments, coinsurance, and out-of-pocket maximums, and Bhargava et al. (2017) showed that when employees at a large firm were offered a menu of plans, most chose options that were financially dominated by alternatives in the same menu, costing them substantial money without additional protection.

 

Value-based insurance design offers an alternative logic. Rather than raising cost-sharing across the board, it lowers or removes cost-sharing for high-value services, such as medications for chronic conditions, while maintaining or increasing it for low-value care (Chernew et al., 2007). The strongest evidence comes from a randomized trial with Aetna members discharged after a heart attack, in which eliminating copayments for evidence-based cardiac medications improved adherence and reduced first major vascular events without increasing total spending (Choudhry et al., 2011).

 

Effective approaches:

 

  • Protect high-value care: Exempt preventive care and chronic-condition medications from deductibles where regulations permit.

  • Target low-value care: Use evidence-based lists of low-value services to focus cost-sharing and utilization management where they reduce waste rather than access.

  • Scale contributions to pay: Tier employee premium contributions by salary band so that cost increases do not fall hardest on lower-paid workers.

  • Simplify choices: Reduce the number of plan options and eliminate dominated plans to make good choices easier.

  • Model distributional effects: Before approving changes, estimate who bears the increase by pay level, family size, and health status.

 

The Aetna trial described by Choudhry et al. (2011) is instructive precisely because it reverses the usual assumption that generosity must cost more. Removing a financial barrier to a high-value medication paid for itself through better adherence and fewer serious cardiovascular events. The large self-insured firm studied by Brot-Goldberg et al. (2017) illustrates the opposite lesson: a plan design intended to make employees savvy consumers instead produced across-the-board reductions in care, including preventive services, without lowering prices.

 

The common pitfall is equating cost-sharing with cost control. Shifting costs to employees reduces the employer's line item but often leaves the total cost of care, and the long-run cost of untreated conditions, unchanged or higher. KFF (2026b) finds that among large firms, 44% raised worker premium shares this year, by far the most common response. Leaders should ask what each design change does to total cost and to health, not only to the employer's share.

 

Make Structured, Evidence-Based GLP-1 Decisions

The third response concerns the most contested coverage question of the moment. The clinical evidence for GLP-1 drugs in obesity is strong: substantial average weight loss in trials (Jastreboff et al., 2022; Wilding et al., 2021) and a 20% reduction in major adverse cardiovascular events in a high-risk population (Lincoff et al., 2023). The economic case for employers is more complicated. Weight is regained after discontinuation (Wilding et al., 2022), real-world persistence is low (Urick et al., 2025), and the benefits of reduced cardiovascular events accrue over years while costs arrive immediately. Employee turnover means that the employer paying for treatment may not be the one that benefits from reduced future claims.

 

Employers have taken divergent paths, and the contrast is illuminating. Some have ended coverage. The State Health Plan of North Carolina ended coverage for weight loss in April 2024 after the number of members using the drugs rose from 2,795 in 2021 to 23,215 in 2023 and projected spending reached about $170 million a year for a plan carrying a large deficit (Stateline, 2025). West Virginia ended a pilot covering about 1,100 enrollees in March 2024 after it cost about $1.3 million a month, with full coverage projected at more than $1 billion a year (Stateline, 2025). The University of Missouri stopped covering GLP-1s for anything other than type 2 diabetes from January 2026, with a spokesperson stating that continuing coverage would have meant a 28% increase in premiums for all employees (KBIA, 2026). Cigna ended GLP-1 weight-loss coverage under its own employee plan from July 2026, and HCA Healthcare told employees it would stop covering Zepbound and Wegovy after reporting a 90% increase in 2025 costs for obesity medications (Leventhal, 2026). Several other health systems, including Allina Health, RWJBarnabas Health, and Ascension, have also stopped covering these drugs for weight loss (Casolo, 2026).

 

Other employers have chosen structured access. The State of Connecticut began covering GLP-1s for weight loss in 2023 and, to manage costs that rose from $7.7 million in 2020 to an estimated $40 million in 2024, required members to enroll in a telehealth lifestyle program first (Stateline, 2025). Jefferson Health, with 65,000 employees, requires participation in diet and lifestyle programs before GLP-1 coverage on its self-funded plan; its chief executive reported savings of $20 million, and the organization says more than 90% of participants remain actively enrolled, with clinicians guiding medication and dosing and dietitians helping manage side effects (Becker's Payer Issues, 2026). KFF (2026b) finds that 40% of covering firms require participation with a dietitian, case manager, therapist, or lifestyle program, rising to 59% among the largest employers.

 

Effective approaches:

 

  • Decide deliberately: Make GLP-1 policy a governed decision with clinical input and explicit criteria, not a default set by a PBM formulary.

  • Structure access: Pair coverage with clinical eligibility criteria and lifestyle, nutrition, or behavioral support that can improve outcomes and persistence.

  • Plan transitions: When narrowing coverage, provide notice, grandfathering or tapering for current users, and clinical guidance on alternatives.

  • Watch the market: Track falling prices, direct-to-employer programs, and new oral formulations, and set a date to revisit the decision.

  • Measure outcomes: Track persistence, clinical outcomes, and total cost, not only drug spend.

 

The contrast between Missouri and Jefferson is instructive. Missouri made a clear, explained decision under acute cost pressure, telling employees that coverage would have required a 28% premium increase for everyone. Jefferson, facing similar pressure, built a clinical pathway that preserved access for those willing to engage while reducing spending. Neither path is costless, and the right choice depends on an organization's financial position, workforce health profile, and values. What distinguishes thoughtful decisions from reactive ones is the presence of criteria, transition planning, and a scheduled review.

 

The pitfall is making a permanent decision about a fast-moving market. Prices for GLP-1 drugs have been falling through direct-to-consumer and direct-to-employer channels; Becker's reports Lilly's employer platform pricing for Zepbound at $449 a month and an oral alternative available to self-paying patients from $149 a month (Casolo, 2026). A decision to drop coverage made in 2026 may look very different in 2028.

 

 

Steer to High-Quality Care

The fourth response focuses on where care happens. Prices and quality vary widely across providers, often with no relationship between the two. Directing employees toward high-quality, efficient providers can improve outcomes and reduce costs at the same time. The KFF survey finds that 24% of employers with 50 or more workers contract with on-site or near-site clinics (KFF, 2026a), and Business Group on Health (2026) reports that 26% of large employers plan to offer an alternative health plan in 2027, often built around high-performance networks.

 

Effective approaches:

 

  • Use centers of excellence: Contract with high-quality providers for planned procedures, covering travel and reducing cost-sharing for employees who use them.

  • Require second opinions: Build expert review into high-cost elective procedures, which can identify cases where surgery is unnecessary.

  • Offer navigation: Provide advocacy or navigation services that help employees find appropriate, high-value providers.

  • Expand access points: Consider on-site, near-site, or virtual primary care where workforce density makes it viable.

  • Pair steering with support: Make the high-value path the easy path through lower cost-sharing and logistical help, rather than penalties alone.

 

Walmart's centers of excellence program, launched in 2013 and expanded to hip and knee replacements in 2014, is the most cited example. Between 2015 and 2018, specialists at program sites determined that about 20% of associates referred for joint replacement would not benefit from surgery. Average cost per case was about 15% lower at centers of excellence ($23,505 versus $27,721), hospital stays were about a third shorter, patients returned to work sooner, and they were 70% less likely to be readmitted (Becker's Spine Review, 2019). In 2018, Walmart introduced a 50% copayment for joint replacements performed outside the network, with exceptions for urgent care, and utilization of the program rose sharply.

 

The pitfall is steering without support. Narrow networks or out-of-network penalties imposed without travel assistance, navigation, and clear communication are experienced as restrictions rather than benefits. Only 7% of large firms moved to narrower networks this year (KFF, 2026b), partly because employees resist them; steering works when the preferred path is visibly better for the employee.

 

Communicate With Candor and Build Literacy

The fifth response cuts across the others. Health insurance is complex, and most employees do not understand it well (Loewenstein et al., 2013). Poor understanding leads to poor choices (Bhargava et al., 2017) and to suspicion when costs rise. Organizational justice research shows that explanations, consistency, and voice substantially shape how people react to unfavorable outcomes (Colquitt et al., 2001). Employees can accept difficult trade-offs when they understand the reasons and believe the process was fair.

 

Effective approaches:

 

  • Explain early: Share cost pressures and options before decisions are final, not only in the enrollment packet.

  • Show the math: Explain how much the organization spends, what drives increases, and how the employer's and employee's shares have changed.

  • Invite input: Use benefits advisory councils, surveys, or focus groups to understand what employees value most.

  • Support decisions: Provide plan-comparison tools, total-cost estimates, and access to counselors during enrollment.

  • Close the loop: Report back on what changed, why, and how the organization will monitor the effects.

 

The University of Missouri's decision illustrates the value of a clear rationale. Rather than quietly removing coverage, the university explained that continuing GLP-1 weight-loss coverage would have required a 28% premium increase for all employees, framing the decision as a trade-off between the needs of some members and affordability for everyone (KBIA, 2026). Whether or not employees agreed, they could see the reasoning. Benefits advisory councils and listening sessions offer one way to build that kind of voice into redesign, consistent with the procedural justice evidence that voice increases acceptance of decisions even when outcomes are unfavorable (Colquitt et al., 2001).

 

The pitfall is treating communication as marketing. Employees quickly see through messages that describe cost increases as "enhancements." Candor about trade-offs builds more trust than optimistic framing, particularly when employees can see that leaders are also making hard choices on the employer side of the ledger.

 

Building Long-Term Benefits Resilience

 

A Multi-Year Affordability Strategy

Annual renewal cycles encourage short-term thinking. A resilient approach sets multi-year targets for total cost of care, employee affordability, and health outcomes, and evaluates every design change against all three. Affordability metrics should be explicit, for example the share of pay that employees at the lowest pay bands spend on premiums and out-of-pocket costs. Organizations can commit to keeping that share below a threshold, which forces trade-offs to be made consciously rather than by default. This mirrors the shift that large employers are already making toward outcome-based vendor contracts and data transparency (Business Group on Health, 2026). The governance structure that supports such a strategy should resemble that of a retirement plan committee: a charter, clear fiduciary roles, documented deliberation, and periodic external review.

 

In practice, a multi-year strategy begins with a baseline: what the organization spends per employee, how that compares with regional and industry benchmarks, how much of the spend flows to hospitals, drugs, and administration, and what employees at each pay level are contributing. From that baseline, leaders can set a small number of commitments, such as holding the lowest-paid employees' contributions flat in real terms, bringing hospital prices closer to a defined benchmark over three years, or achieving full transparency in pharmacy contracts by a set date. Each year's renewal then becomes a step toward those commitments rather than a fresh negotiation from scratch. Leaders should also build in scenario planning for shocks, such as a new high-cost therapy or a cluster of catastrophic claims, so that the response to the next surprise is planned rather than improvised.

 

Health as a Workforce Capability

The second pillar treats health as part of workforce capability rather than an expense to minimize. That means investing in interventions with credible evidence and being skeptical of those without it. Randomized studies of conventional workplace wellness programs, including a large trial at BJ's Wholesale Club and the Illinois Workplace Wellness Study, found little effect on clinical outcomes or spending in the short run, partly because healthier employees self-selected into participation (Jones et al., 2019; Song & Baicker, 2019). Resources are better directed toward access to primary care, management of chronic conditions, mental health, and evidence-based obesity treatment pathways, with measurement built in. Organizations that understand their workforce's health profile through aggregated, privacy-protected claims data can target investment where it matters most.

 

This pillar also requires closer collaboration between HR, finance, and clinical expertise. Benefits teams that work in isolation tend to default to the levers they control, mainly plan design and contributions. When medical directors, occupational health professionals, and finance partners share a common view of the data, organizations are better able to distinguish spending that reflects unmet need from spending that reflects waste, and to invest accordingly. For GLP-1 drugs in particular, the question is less whether to spend and more how to ensure that spending translates into durable health gains, which depends on clinical support, persistence, and integration with primary care.

 

Fairness and Voice in Total Rewards

The third pillar recognizes that health benefits are part of a broader psychological contract. Rhoades and Eisenberger (2002) and Kurtessis et al. (2017) show that perceived organizational support is built through discretionary, visible investments in employee wellbeing. Health benefits are among the most visible. When costs must be shared, doing so in proportion to ability to pay, with notice and explanation, protects the perception of fairness. Building employee voice into benefits decisions through advisory councils, transparent reporting, and periodic listening turns a source of friction into a source of trust. Over time, organizations that are seen as careful stewards of employees' health dollars earn the latitude to make difficult decisions when they are needed.

 

Conclusion


The 2026 KFF survey confirms what employees already feel: health coverage is becoming more expensive faster than paychecks are growing, and the pressure is likely to intensify in 2027. The default organizational response, raising employee contributions and deductibles, is understandable but costly in ways that rarely appear in the renewal: reduced use of valuable care, financial strain, weakened trust, and, eventually, wages that grow more slowly because health costs absorb the difference. GLP-1 drugs have become the focal point of this dilemma because they combine clear clinical benefit with large, immediate costs and uncertain long-term returns for any single employer.

 

A better path is available. It treats benefits as a governed investment, designs plans around value, structures access to expensive therapies rather than defaulting to all-or-nothing decisions, steers care toward quality, and communicates with candor. None of this is easy, and none of it eliminates hard trade-offs. But organizations that take this path are likely to spend their health dollars more effectively and to keep the trust of the people those dollars are meant to protect.

 

Practical takeaways for leaders:

 

  • Know what you buy: Secure full access to claims, pricing, and rebate data and audit your PBM and administrators regularly.

  • Measure affordability: Track what employees at each pay level spend on premiums and out-of-pocket costs, and set targets.

  • Protect high-value care: Shield preventive care and chronic-condition medications from cost-sharing, and target low-value care instead.

  • Govern GLP-1 decisions: Use clinical criteria, support pathways, transition plans, and a scheduled review rather than an all-or-nothing default.

  • Steer with support: Use centers of excellence, navigation, and second opinions, making the high-value path the easy one.

  • Explain the trade-offs: Share the numbers and the reasoning early, and invite employee input before decisions are final.

  • Think in years, not renewals: Build a multi-year strategy with fiduciary-style governance and outcome measures.

 

Research Infographic



 

References


  1. Baicker, K., & Chandra, A. (2006). The labor market effects of rising health insurance premiums. Journal of Labor Economics, 24(3), 609–634.

  2. Bannow, T. (2026, October 22). KFF health benefits survey finds 9% price hike, hints of a 'breaking point'. STAT.

  3. Becker's Payer Issues. (2026, April 20). How Jefferson Health is coping with GLP-1 pressures in insurance coverage. Becker's Payer Issues.

  4. Becker's Spine Review. (2019). Walmart's centers of excellence program cut joint replacement costs by 15%: 5 things to know. Becker's Spine Review.

  5. Bhargava, S., Loewenstein, G., & Sydnor, J. (2017). Choose to lose: Health plan choices from a menu with dominated option. Quarterly Journal of Economics, 132(3), 1319–1372.

  6. Brot-Goldberg, Z. C., Chandra, A., Handel, B. R., & Kolstad, J. T. (2017). What does a deductible do? The impact of cost-sharing on health care prices, quantities, and spending dynamics. Quarterly Journal of Economics, 132(3), 1261–1318.

  7. Buchanan Ingersoll & Rooney. (2025, April 4). Wells Fargo's ERISA dismissal and Johnson & Johnson's second try: The stakes for employer fiduciaries. Buchanan Ingersoll & Rooney PC.

  8. Business Group on Health. (2026). 2027 employer health care strategy survey. Business Group on Health.

  9. Casolo, E. (2026, April 27). Employers' GLP-1 coverage dilemma grows. Becker's Hospital Review.

  10. Chernew, M. E., Rosen, A. B., & Fendrick, A. M. (2007). Value-based insurance design. Health Affairs, 26(2), w195–w203.

  11. Choudhry, N. K., Avorn, J., Glynn, R. J., Antman, E. M., Schneeweiss, S., Toscano, M., Reisman, L., Fernandes, J., Spettell, C., Lee, J. L., Levin, R., Brennan, T., & Shrank, W. H. (2011). Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine, 365(22), 2088–2097.

  12. Colquitt, J. A., Conlon, D. E., Wesson, M. J., Porter, C. O. L. H., & Ng, K. Y. (2001). Justice at the millennium: A meta-analytic review of 25 years of organizational justice research. Journal of Applied Psychology, 86(3), 425–445.

  13. Consolidated Appropriations Act, 2021, Pub. L. No. 116-260, 134 Stat. 1182 (2020).

  14. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.

  15. Jones, D., Molitor, D., & Reif, J. (2019). What do workplace wellness programs do? Evidence from the Illinois Workplace Wellness Study. Quarterly Journal of Economics, 134(4), 1747–1791.

  16. Journal of Accountancy. (2023, June). How a CPA saved a state millions in health care costs. Journal of Accountancy.

  17. KBIA. (2026, March 25). Mizzou joins other insurers in cutting GLP-1 weight-loss drug coverage. KBIA.

  18. KFF. (2026a, October 22). Workers now pay $7,471 on average annually for family health coverage, up 9% or $621 from 2025, benchmark Employer Health Benefits Survey finds [Press release]. KFF.

  19. KFF. (2026b). 2026 Employer Health Benefits Survey. KFF.

  20. Kurtessis, J. N., Eisenberger, R., Ford, M. T., Buffardi, L. C., Stewart, K. A., & Adis, C. S. (2017). Perceived organizational support: A meta-analytic evaluation of organizational support theory. Journal of Management, 43(6), 1854–1884.

  21. Leventhal, R. (2026, June 3). Weight loss drugs' high costs prompt Cigna to cut employee health plan coverage. eMarketer.

  22. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232.

  23. Loewenstein, G., Friedman, J. Y., McGill, B., Ahmad, S., Linck, S., Sinkula, S., Beshears, J., Choi, J. J., Kolstad, J., Laibson, D., Madrian, B. C., List, J. A., & Volpp, K. G. (2013). Consumers' misunderstanding of health insurance. Journal of Health Economics, 32(5), 850–862.

  24. Lopes, L., Kearney, A., Montero, A., Hamel, L., & Brodie, M. (2022). Health care debt in the U.S.: The broad consequences of medical and dental bills. KFF.

  25. Madrian, B. C. (1994). Employment-based health insurance and job mobility: Is there evidence of job-lock? Quarterly Journal of Economics, 109(1), 27–54.

  26. Marsh. (2026, September 2). Employers expect health benefit costs to jump in 2027 [Press release]. Marsh.

  27. NPR. (2026, April 22). Restrictions on obesity drug coverage force patients to pivot. NPR.

  28. PlanAdviser. (2025, December 5). J&J employee benefits case dismissed for second time. PlanAdviser.

  29. Rhoades, L., & Eisenberger, R. (2002). Perceived organizational support: A review of the literature. Journal of Applied Psychology, 87(4), 698–714.

  30. Song, Z., & Baicker, K. (2019). Effect of a workplace wellness program on employee health and economic outcomes: A randomized clinical trial. JAMA, 321(15), 1491–1501.

  31. Stateline. (2025, January 21). States consider high costs, possible savings of covering weight-loss drugs for their workers. Stateline.

  32. Urick, B., Marshall, L., & Gleason, P. (2025). GLP-1 therapy to treat obesity among members without diabetes: Three-year persistence and year-over-year persistence rate change. Prime Therapeutics.

  33. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.

  34. Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., & Kushner, R. F. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564.

  35. Zhao, H., Wayne, S. J., Glibkowski, B. C., & Bravo, J. (2007). The impact of psychological contract breach on work-related outcomes: A meta-analysis. Personnel Psychology, 60(3), 647–680.

Jonathan H. Westover, PhD, Chief Research Officer (Nexus Institute for Work and AI); Co-Founder & Chief Workforce and Learning Officer (Future State University); Founder & CEO (Human Capital Innovations); Professor of Organizational Leadership & Change (UVU). Read Jonathan Westover's executive profile here.

Suggested Citation: Westover, J. H. (2026). The Benefits Breaking Point: Rising Health Costs, the GLP-1 Dilemma, and How Leaders Can Keep Coverage Affordable, Fair, and Worth Having. Human Capital Leadership Review, 40(4). doi.org/10.70175/hclreview.2020.40.4.6



Human Capital Leadership Review

eISSN 2693-9452 (online)

future of work collective transparent.png
Renaissance Project transparent.png

Subscription Form

HCI Academy Logo
Effective Teams in the Workplace
Employee Well being
Fostering Change Agility
Servant Leadership
Strategic Organizational Leadership Capstone
bottom of page